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Abstract
Virtually all the compounds that are currently used, or are subject of advanced clinical trials, for the treatment of human
immunodeficiency virus (HIV) infections, belong to one of the following classes: (i) nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs): i.e. zidovudine (AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC), emtricitabine
[( )FTC], tenofovir disoproxil fumarate; (ii) non-nucleoside reverse transcriptase inhibitors (NNRTIs): i.e. nevirapine, delavirdine,
efavirenz, emivirine; and (iii) protease inhibitors (PIs): i.e. saquinavir, ritonavir, indinavir, nelfinavir, amprenavir and lopinavir. In addition to
the reverse transcriptase (RT) and protease reaction, various other events in the HIV replicative cycle can be considered as potential targets for
chemotherapeutic intervention: (i) viral adsorption, through binding to the viral envelope glycoprotein gp120 (polysulfates, polysulfonates,
polycarboxylates, polyoxometalates, polynucleotides, and negatively charged albumins); (ii) viral entry, through blockade of the viral
coreceptors CXCR4 [bicyclam (AMD3100) derivatives] and CCR5 (TAK-779 derivatives); (iii) virus–cell fusion, through binding to the
viral envelope glycoprotein gp41 (T-20, T-1249); (iv) viral assembly and disassembly, through NCp7 zinc finger-targeted agents [2,2V-
dithiobisbenzamides (DIBAs), azadicarbonamide (ADA)]; (v) proviral DNA integration, through integrase inhibitors such as 4-aryl-2,4-
dioxobutanoic acid derivatives; (vi) viral mRNA transcription, through inhibitors of the transcription (transactivation) process (flavopiridol,
fluoroquinolones). Also, various new NRTIs, NNRTIs and PIs have been developed that possess, respectively: (i) improved metabolic
characteristics (i.e. phosphoramidate and cyclosaligenyl pronucleotides by-passing the first phosphorylation step of the NRTIs), (ii) increased
activity [‘‘second’’ or ‘‘third’’ generation NNRTIs (i.e. TMC-125, DPC-083)] against those HIV strains that are resistant to the ‘‘first’’
generation NNRTIs, or (iii) as in the case of PIs, a different, nonpeptidic scaffold [i.e. cyclic urea (mozenavir), 4-hydroxy-2-pyrone
(tipranavir)]. Nonpeptidic PIs may be expected to inhibit HIV mutant strains that have become resistant to peptidomimetic PIs. Given the
multitude of molecular targets with which anti-HIV agents can interact, one should be cautious in extrapolating the mode of action of these
agents from cell-free enzymatic assays to intact cells. Two examples in point are L-chicoric acid and the nonapeptoid CGP64222, which were
initially described as an integrase inhibitor or Tat antagonist, respectively, but later shown to primarily act as virus adsorption/entry inhibitors,
the latter through blockade of CXCR4. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Combination therapy, comprising at least three anti-
human immunodeficiency virus (HIV) drugs, has become
the standard treatment of acquired immune deficiency
syndrome (AIDS) or HIV-infected patients. Virtually all
drugs that have been licensed for clinical use (or made
available through expanded access programmes) for the
treatment of HIV infections fall into one of the following
three categories: (i) nucleoside/nucleotide reverse transcrip-
tase inhibitors (NRTIs), that, following two phosphorylation
steps (tenofovir) or three phosphorylation steps [zidovudine
(AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T),
lamivudine (3TC), abacavir (ABC)], act, as chain termina-
tors, at the substrate binding site of the reverse transcriptase
(RT); (ii) non-nucleoside reverse transcriptase inhibitors
(NNRTIs) that interact with the RT at an allosteric, non-
substrate binding site (nevirapine, delavirdine, efavirenz);
and (iii) protease inhibitors (PIs) that specifically inhibit, as
peptidomimetics, the virus-associated protease (saquinavir,
ritonavir, indinavir, nelfinavir, amprenavir, lopinavir).
Guidelines to the major clinical trials with these compounds
have been recently published [1].
Although the long-term goal of eradicating the virus from
latently and chronically infected cells remains forbidding [2],
the advent of so many new compounds other than those that
have been formally approved, for the treatment of HIV
infections, will undoubtedly improve the prognosis of
patients with AIDS and AIDS-associated diseases. Here, I
will primarily address those new anti-HIV compounds that (i)
have emerged as promising anti-HIV drug candidates during
the last few years, that (ii) are in preclinical or early-clinical
development, and that (iii) are targeted at well-defined steps
in the HIV replicative cycle.
2. Virus adsorption (gp120) inhibitors
A great variety of polyanionic compounds have been
described to block HIV replication through interference with
virus adsorption (or binding) to the cell surface: i.e. poly-
sulfates, polysulfonates, polycarboxylates, polyphosphates,
polyphosphonates, polyoxometalates, etc. This class of
compounds also comprises the cosalane analogues (1) con-
taining the polycarboxylate pharmacophore [3], as well as
the sulfated polysaccharides extracted from sea algae [4].
All these compounds, whether synthetic or of natural origin,
are assumed to exert their anti-HIV activity by shielding off
the positively charged sites in the V3 loop of the viral
envelope glycoprotein (gp120) [5,6], which is necessary for
virus attachment to the cell surface heparan sulfate, a
primary binding site, before a more specific binding occurs
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to the CD4 receptor of the CD4+ cells, and to the CXCR4
coreceptor of the CXCR4+ cells (the latter in the case of X4
and dual tropic X4/R5 HIV strains). Heparan sulfate is
widely expressed on animal cells and, as it is involved in
the virus-cell binding of a broad spectrum of enveloped
viruses, including herpes simplex virus (HSV) [7], dengue
virus [8] and other flaviviruses (i.e. Japanese encephalitis
virus) [9], it also explains why polysulfates have a broad-
spectrum antiviral activity against HIV, HSV and various
other enveloped viruses [10].
The major role of polysulfates or polyanionic substances
in general in the management of HIV infections may reside
in the prevention of sexual transmission of HIV infection, as
these compounds, if applied as a vaginal formulation, may
successfully block HIV infection through both virus-to-cell
and cell-to-cell contact. These compounds therefore merit
being pursued as vaginal microbicides. The fact that in
addition to their anti-HIV activity, these polyanionic sub-
stances, as demonstrated, for example, for poly(sodium(4-
styrene)sulfonate), also inhibit other sexually transmitted
disease (STD) pathogens, i.e. HSV, Neisseria gonorrheae
and Chlamydia trachomatis [11], further adds to their
potential therapeutic and preventive value.
3. Viral coreceptor antagonists
To enter cells, following binding with the CD4 receptor,
the HIV-1 particles must interact, again through the viral
envelope glycoprotein gp120, with the CXCR4 coreceptor
[12] or CCR5 coreceptor [13]. CXCR4 is the coreceptor for
HIV-1 strains that infect T-cells (T-tropic or X4 strains), and
CCR5 is the coreceptor for HIV-1 strains that infect macro-
phages (M-tropic or R5 strains). CXCR4 and CCR5 have
not evolved simply to act as coreceptors for HIV entry; they
normally act as receptors for chemokines (chemoattractant
cytokines). The normal ligands for CCR5 are RANTES
(‘‘regulated upon activation, normal T-cell expressed and
secreted’’) and MIP-1a and -1h (‘‘macrophage inflamma-
tory proteins’’), whereas for CXCR4, only one natural
ligand, namely SDF-1 (‘‘stromal-cell derived factor’’) has
been identified. Of these chemokines, the LD78h isoform of
MIP-1a has emerged as the most potent chemokine for
inhibiting HIV-1 infection in peripheral blood mononuclear
cells (PBMCs) [14,15] as well as monocytes/macrophages
[16].
TAK-779, a quaternary ammonium derivative (2) is the
first nonpeptidic molecule that has been described to block
the replication of M-tropic R5 HIV-1 strains at the CCR5
level [17].
A binding site for TAK-779 has been identified within
the transmembrane helices 1, 2, 3 and 7 of CCR5 [18].
TAK-779 has been found to inhibit R5 HIV-1 strains in the
nanomolar concentration range, while not affecting X4
HIV-1 strains at 10,000-fold higher concentrations [17].
TAK-779 is not a ‘‘pure’’ CCR5 antagonist, as it also
demonstrates some antagonism towards CCR2b. Unlike
RANTES, TAK-779 does not induce internalization of
CCR5. The clinical potential of TAK-779 and its conge-
ners [19] in the therapy and/or prophylaxis of HIV-1
infections remains to be further explored. Meanwhile,
several new CCR5 antagonists have been reported
[20,21], and a lead clinical candidate (SCH C) for further
development has been identified.
Almost simultaneously [22–24], three compounds, i.e.
the bicyclam AMD3100 [22], [Tyr-5,12,Lys-7]polyphemu-
sin or T22 [23] and the nonapeptide (D-Arg)9 or ALX40-
4C [24] were announced as CXCR4 antagonists, blocking
the replication of T-tropic X4, but not M-tropic R5, HIV-1
strains through selective antagonism of CXCR4. The
bicyclams are the most specific and most potent CXCR4
antagonists that have been described to date [25,26]. The
bicyclams had been known as potent and selective HIV
inhibitors for a number of years [27,28], before their
target of action was identified as the CXCR4 coreceptor
[22,29,30]. The bicyclam AMD3100 (3) inhibits the
replication of X4 HIV-1 strains within the nanomolar
concentration range [28]. As it is not toxic to the host
cells at concentrations up to 500 AM, its selectivity index,
or ratio of 50% cytotoxic concentration (CC50) to 50%
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antivirally effective concentration (EC50) can be estimated
at > 100,000.
A close correlation has been found, over a concentration
range of 0.1–1000 ng/ml, between the AMD3100 con-
centrations required to inhibit (i) HIV-1 NL4-3 replication,
(ii) monoclonal antibody (mAb 12G5) binding to the
CXCR4 coreceptor, and (iii) SDF-1-induced signal trans-
duction (Ca2+ flux), suggesting an intimate relationship
between these three parameters [29,30]. The inhibitory
effects of AMD3100 on the T-tropic HIV-1 NL4-3 strain
have been demonstrated in a wide variety of cells expressing
CXCR4, including PBMCs; and, vice versa, various T-
tropic and dual-tropic, but not M-tropic, HIV-1 strains have
proven sensitive to AMD3100 in PBMC.
Negatively charged amino acid (i.e. aspartic acid) resi-
dues in the extracellular regions of CXCR4 must be
involved in its interaction with both AMD3100 and SDF-
1, and the V3 loop of X4 HIV gp120, which are all three
highly basic. Substitutions of a neutral amino acid residue
for aspartic acid in the second extracellular loop generated
resistance to AMD3100 [31]. In particular, the aspartate
residues at positions 171 and 262, located close to the
extracellular sides of the transmembrane segments TM4
and TM6, may represent crucial sites of interaction with
the bicyclam AMD3100 [32].
When the bicyclam AMD3100 was added to PBMC
infected with clinical HIV isolates displaying the syncy-
tium-inducing (SI) phenotype, these strains reverted to the
non-syncytium-inducing (NSI) phenotype, and, concomi-
tantly, these strains switched from CXCR4 to CCR5 cor-
eceptor use [33]. These findings indicate that selective
blockade of CXCR4 by AMD3100 may prevent the switch
from the less pathogenic M-tropic R5 to the more patho-
genic T-tropic X4 strains of HIV, which in vivo heralds the
progression to AIDS. AMD3100 has proved efficacious,
alone and in combination with other anti-HIV drugs, in
achieving a marked reduction in viral load in the SCID-hu
Thy/Liv mouse model [34]. Following a phase I clinical trial
for safety in normal healthy volunteers [35], AMD3100
recently entered phase II clinical trials in HIV-infected
individuals.
Given their high potency and selectivity as CXCR4
antagonists, bicyclams, such as AMD3100, may not only
have great potential for the therapy and/or prophylaxis of
X4 HIV infections, but also other pathologic processes,
such as breast cancer metastasis, which are at least partially
dependent of, or mediated by, signaling through CXCR4
[36].
4. Viral fusion (gp41) inhibitors
The interaction of the X4 or R5 HIV-1 envelope gly-
coprotein gp120 with the coreceptor CXCR4 or CCR5,
respectively, is followed by a spring-loaded action of the
viral glycoprotein gp41 (normally covered by the bulkier
gp120), which then anchors through its amino terminus
(the ‘‘fusion peptides’’) into the target cell membrane. This
initiates the fusion of the two lipid bilayers, that of the
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viral envelope with that of the cellular plasma membrane
[37]. At the onset of the fusion process, the hydropho-
bic grooves on the surface of the N36 coiled coil in the
gp41 ectodomain become available for binding with ex-
traneous inhibitors, such as DP-178 (T-20), a 36-residue
peptide, that binds to the hydrophobic groove of N36
[37].
T-20 (pentafuside) (4) is a synthetic, 36-amino acid
peptide corresponding to residues 127–162 of the ectodo-
main of gp41 (or residues 643–678 in the gp160 pre-
cursor). T-20, previously called DP-178, was modeled
after a specific domain (within gp41) predictive of a-
helical secondary structure: DP-178 consistently afforded
100% blockade of virus-mediated cell–cell fusion (syncy-
tium formation) at concentrations ranging from 1 to 10 ng/
ml, i.e. 104- to 105-fold lower than the cytotoxic concen-
tration [38]. An initial clinical trial has been carried out
with T-20 at four doses (3, 10, 30 and 100 mg twice daily,
intravenously, for 14 days) in 16 HIV-infected adults: at
the highest dose (100 mg, twice daily), T-20 achieved by
the 15th day a 1.5- to 2.0-fold reduction in plasma HIV
RNA [39]. These data provide proof-of-concept that HIV
fusion inhibitors are able to reduce virus replication in
vivo.
Meanwhile, T-20 has proceeded to phase II/III clinical
trials, and phase I clinical trials have been initiated with T-
1249, a 39-amino acid peptide derived from DP-107 (which
is a 38-amino acid peptide corresponding to residues 558–
595 of gp160); T-1249 would be 10-fold more potent than
T-20 when evaluated in vitro against HIV under the same
conditions [40].
The betulinic acid derivative RPR 103611 (5) is the
only nonpeptidic low-molecular-weight compound that has
been reported to block HIV-1 infection through interaction
with gp41: this triterpene derivative has been found to
inhibit the infectivity of a number of HIV-1 strains in the
10 nM concentration range [41], apparently through inter-
ference with a post-binding, envelope-dependent step
involved in the fusion of the virus with the cell plasma
membrane.
The exact mode of action of RPR 103611 remains to be
elucidated. Sequence analysis of RPR103611-resistant mu-
tants indicated that a single amino acid change, I84S, in
HIV-1 gp41 is sufficient to confer drug resistance [42].
However, this I84S mutation did not occur in some of the
naturally RPR103611-resistant HIV-1 strains such as NDK.
More recently, the action of RPR103611 has been thought to
depend on the accessibility of gp41 [43], and for the
isomeric betulinic acid derivative IC 9564, HIV-1 gp120,
rather than gp41, has been proposed as the prime target
(based on the mutations G237R and R252K emerging in
gp120 of drug-resistant mutants) [44]. YK-FH312, a betu-
linic acid derivative unrelated to RPR103611 or IC 9564,
was reported to block the assembly and/or budding of HIV
particles [45].
5. Nucleocapsid protein (NCp7) Zn finger-targeted
agents
The two zinc fingers [Cys-X2-Cys-X4-His-X4-Cys
(CCHC), whereby X = any amino acid] in the nucleocapsid
(NCp7) protein [46] comprise the proposed molecular target
for zinc-ejecting compounds such as 3-nitrosobenzamide
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(NOBA), 2,2V-dithiobisbenzamide (DIBA), SRR-SB3
(cyclic DIBA) [47], 1,2-dithiane-4,5-diol,1,1-dioxide (di-
thiane) [48] and azadicarbonamide (ADA) [49,50]. These
compounds should be able to interfere with both early
(uncoating, disassembly) and late phases (packaging, assem-
bly) of retrovirus replication. Their effect at the early phase
(disassembly) may also be ascribed to cross-linkage among
adjacent zinc fingers. The DIBAs are able to enter intact
virions and the cross-linkage of NCp7 in virions correlates
with loss of infectivity and decreased proviral DNA syn-
thesis during acute infection [51]. Electron microscopically,
the effect bestowed by DIBAs on virus morphology could
be described as ‘‘core-freezing’’ [52].
Although NOBA, DIBA, dithiane and ADA have been
shown to dock nicely on the NCp7 Zn finger domains [53]
and are believed to selectively target these Zn fingers
without affecting the cellular Zn finger proteins, their
selectivity indexes [ratio of CC50 (50% cytotoxic concen-
tration) over EC50 (50% effective concentration)] are not
that impressive [53]. Of the NCp7-targeted compounds,
ADA (6) has been the first to proceed to phase I/II clinical
trials in advanced AIDS patients. Some preliminary evi-
dence of efficacy was witnessed with add-on ADA in
patients failing current antiretroviral therapy [54]; these
studies should be further extended. Although ADA is an
HIV NCp7 Zn-finger inhibitor, its action in vivo is likely to
be multipronged. ADA may well interact with a variety of
targets and, certainly, its inhibitory effects on T-cell
responses in vitro and in vivo [55] can hardly be attributed
to an action targeted at the HIV NCp7 Zn fingers.
6. RT inhibitors targeted at the substrate binding site
The substrate (dNTP) binding site of the HIV-1 RT is the
target for a large variety of NRTI analogues, which have for
several years [56] been recognized as efficacious drugs for
the treatment of HIV infections: i.e. AZT, ddI, ddC, d4T,
3TC, ABC, and the yet experimental drug emtricitabine
[( )FTC]. Fozivudine tidoxil is a thioether lipid AZT
conjugate that has recently passed phase II clinical trials
[57] and should be as effective as, and potentially better
tolerated than, AZT. As a rule, all these compounds must be
phosphorylated to their 5V-triphosphate form, before they can
act as competitive inhibitors/substrate analogues/chain ter-
minators at the RT level. In contrast to the nucleoside
analogues, the nucleotide analogues PMEA and PMPA are
already equipped with a phosphonate group, and therefore
only need two phosphorylation steps to be converted to the
active metabolite [58]. From PMEA and PMPA, the oral
prodrug forms [bis(pivaloyloxymethyl)-9-(2-phosphonylme-
thoxyethyl)adenine (bis(POM)-PMEA) or adefovir dipi-
voxyl (7), and bis(isopropyloxycarbonyloxymethyl)-(R)-9-
(2-phosphonylmethoxypropyl)adenine (bis(POC)-PMPA) or
tenofovir disoproxil (8) fumarate, respectively] have been
prepared. The former is in advanced phase III clinical trials
for the treatment of hepatitis B virus (HBV) infections,
whereas the latter has completed phase III clinical trials for
the treatment of HIV infections. A new drug application
(NDA) and market authorization application (MAA) has
been recently filed for tenofovir disoproxil fumarate with
the FDA (US) and EMEA (EU), respectively. In rhesus
macaques infected with the highly pathogenic chimeric virus
SHIV, tenofovir treatment initiated 1 week post-infection, at
a time when disseminated infection and extensive viral
replication had already been established and CD4 + T-cell
loss had begun, led to prompt, virtually complete suppres-
sion of viral replication and long-term stabilization of CD4 +
T-cell levels, which were sustained, even after withdrawal of
tenofovir (after 12 weeks of treatment) [59].
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In addition to 3TC and ( )FTC, the structurally related
(F )2V-deoxy-3V-oxa-4V-thiocytidine (BCH-10652,dOTC)
[60], the dioxolane purine nucleoside analogues [61], the
methylenecyclopropane nucleoside analogues (and their
phosphoro-L-alaninate diesters) [62,63] and the 4V-ethynyl
nucleoside analogues [64] have recently been described as
new anti-HIV agents. [( )FTC] (9) is in phase III trials for
HIV and phase I/II trials for HBV; it is considered for use
in the multidrug combination therapy of HIV-1 and HBV
infections. Amdoxovir [DAPD, ( )-h-D-2,6-diaminopur-
ine dioxolane] (10), which is converted by adenosine
deaminase to dioxolane guanine (DXG), has proven active
against AZT- and 3TC-resistant HIV-1 strains and has
proceeded to phase I/II clinical studies [65,66]. BCH-
10652 (dOTC) (11) has demonstrated activity against
HIV-1 in the SCID-hu Thy/Liv model. Despite its struc-
tural similarity to 3TC, dOTC proved also active against
3TC-resistant HIV-1 (M184V), albeit at a relatively high
dosage level (400 mg/kg/day) [67]. Also in vitro, dOTC and
its (+) and ( ) enantiomers still retained, albeit reduced,
activity against 3TC-resistant M184V and M184I HIV-1
mutants [68].
The bottleneck in the metabolic pathway leading from
AZT and the other 2V,3V-dideoxynucleoside (ddN) ana-
logues to their active 5V-triphosphate form is the first
phosphorylation step. Therefore, attempts have been made
at constructing 2V,3V-dideoxynucleotide (ddNMP) prodrugs
that, once they have been taken up by the cells, deliver
the nucleotide (ddNMP) form. This approach has proven
particularly successful for a number of NRTIs such as
2V,3V-dideoxyadenosine (ddA) and d4T. Thus, the bis(S-
acetyl-2-thioethyl)phosphotriester of ddA [bis(SATE]d-
dAMP] (12) was synthesized and found to be 1000-fold
more potent against HIV than the parent compound ddA
[69]. Similarly, aryloxyphosphoramidate derivatives of
d4T [i.e. So324, a d4T-MP prodrug containing at the
phosphate moiety a phenyl group and the methylester of
alanine linked to the phosphate group through a phos-
phoramidate linkage] have been constructed [70–72].
After the d4T aryloxyphosphoramidate (13) has been
taken up by the cells, d4TMP is released intracellularly
and then processed onto its active metabolite d4TTP
[73]. This ‘‘thymidine kinase bypass’’ explains the high
anti-HIV activity of d4T aryloxyphosphoramidate deriva-
tives in thymidine kinase deficient cells and resting mono-
cytes/macrophages [74]. The thymidine kinase (in the
case of d4T) and the adenosine deaminase (in the case
of ddA) can also be bypassed by using the cyclic sali-
genyl approach [75,76]. Cyclosaligenyl pronucleotides of
d4T and ddA deliver exclusively the nucleotides d4TMP
and ddAMP, not only under chemical-simulated hydrol-
ysis conditions but also under intracellular conditions
[77,78]. This has been convincingly shown for the cyclo-
saligenyl derivative of d4TMP (14) in a number of cell
lines [79].
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7. RT inhibitors targeted at the allosteric, nonsubstrate
binding site
More than 30 structurally different classes of com-
pounds have been identified as NNRTIs, viz. compounds
that are specifically inhibitory to HIV-1 replication and
targeted at a nonsubstrate binding site of the RT [80].
Three NNRTIs (nevirapine, delavirdine and efavirenz)
have so far been formally licensed for clinical use in the
treatment of HIV-1 infections, emivirine (MKC-442) (15)
is in advanced (phase III) clinical trials, and others are in
preclinical or early clinical development. The NNRTIs
interact with a specific ‘‘pocket’’ site of the HIV-1 RT
[81], which is closely associated with, but distinct from,
the substrate binding site. NNRTIs are notorious for
rapidly eliciting resistance [82], resulting from mutations
at the amino acid residues that surround the NNRTI-bind-
ing site of HIV-1 RT. However, emergence of NNRTI-
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resistant HIV strains can be prevented if the NNRTIs are
combined with NRTIs and used from the beginning at
sufficiently high concentrations [80].
The thiocarboxanilide UC-781 (16) is an exceptionally
potent inhibitor of HIV-1 replication [80]. It has been found
to restore the antiviral activity of AZT against AZT-resistant
HIV-1 [83]. UC-781 has been recognized as a (retro)viru-
cidal agent, capable of reducing the infectivity of HIV-1
virions, and, therefore, yielding considerable promise for the
use in (retro)virucidal formulations to prevent the trans-
mission of HIV from infected to noninfected individuals
[84]. UC-781 would seem an ideal candidate for application
as a vaginal microbicide (virucide), i.e. when formulated in
replens gel [85].
To the new classes of NNRTIs that offer potent anti-HIV-
1 activity belong the thieno[3,4][1,2,4]thiadiazine derivative
QM96521 [86], the quinoxaline GW420867X [87], the
imidazole derivative S-1153 (AG1549, capravirine) [88–
90], ( )-6-chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-
4-pyrimidinamine (PNU-142721) [91], N-[2-(2,5-dimethox-
yphenylethyl]-NV-[2-(5-bromopyridyl]-thiourea (HI-236)
[92], the pyrido[1,2a]indole derivative BCH-1 [93], the 4-
cyclopropylalkynyl-4-trifluoromethyl-3,4-dihydro-2(1H)
quinazolinones DPC 961 and DPC 963, the 4-cyclopropylal-
kenyl-4-trifluoromethyl-3,4-dihydro-2(1H)quinazolinones
DPC 082 and DPC 083 [94], the thiophene-ethylthiourea
(TET) derivative HI-443 [95], the cyclohexenylethylthiourea
derivatives HI-346 and HI-445 [96], the cis-cyclopropyl
urea-PETT derivatives [97], the alkenyldiarylmethane
(ADAM) series of compounds [98], the pyrrolobenzoxaze-
pinone (PBO) derivatives [99], the quinoxalinylethylpyridyl
thioureas (QXPTs) [100], the emivirine (MKC-442) deriv-
ative SJ-3366 [101] and R165335(TMC125) [102]. As a
rule, the ‘‘new’’ (‘‘second’’ or ‘‘third’’ generation) NNRTIs
exhibit higher potency than the ‘‘old’’ (‘‘first’’ generation)
NNRTIs against wild-type and NNRTI-resistant HIV-1
[91,94–96,99,102]. This is particularly prominent for
DPC 083 (17) and R165335 (TMC125) (18) that showed
activity against L100I, K103N, Y181C, Y188L,
K103N+L100I and K103N +Y181C RT mutant strains in
the nanomolar concentration range [102]. This makes
R165335 (TMC125) an excellent candidate for further
clinical development.
Some of the new NNRTIs, such as SJ-3366 (19), possess
remarkable features. This compound was reported to inhibit
HIV-1 replication at a concentration below 1 nM with a
therapeutic index greater than 4,000,000, and to inhibit HIV-
2 replication (albeit at higher concentrations than those
required for inhibition of HIV-1) at the viral entry stage
[101].
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Capravirine (AG1549) (20) has a favorable profile of
resilience to many drug resistance mutations, which has been
attributed to extensive main chain hydrogen bonding involv-
ing the main chain of residues 101, 103, and 236 of the p66
RT subunit [89]. Capravirine has proceeded to phase II/III
clinical trials [90].
The NNRTIs cis-cyclopropylurea-PETT [97] and PBO
derivatives [99] are orally bioavailable and penetrate well
into the brain. The broad, potent antiviral activity, and
favorable pharmacokinetic profile, have led to the selection
of PNU-142721 (21) for clinical studies [91]; and DPC 961,
DPC 963, DPC 082 and DPC 083 for clinical development
[94].
(+)-Calanolide A (22) is the only naturally occurring
NNRTI: it was first isolated from a tropical tree (Calophyl-
llum lanigerum) and has already been the subject of a phase
I clinical study in healthy, HIV-negative individuals [103].
Recently, an unexpected effect of NNRTIs on HIV-1 RT
dimerization was documented [104]: several NNRTIs,
including efavirenz, were found to enhance the association
between the RT subunits p66 and p51, apparently due to a
conformational change in the p66 subunit that resulted in
enhanced binding to the p51 subunit. It remains to be
established if this enhanced dimerization has any bearing
on the anti-HIV-1 potency of the NNRTIs.
8. HIV integrase inhibitors
Retrovirus integration requires at least two viral com-
ponents, the retroviral enzyme integrase, and cis-acting
sequences at the retroviral DNA termini U3 and U5 ends
of the long terminal repeats (LTRs). Since HIV, like other
retroviruses, cannot replicate without integration into a
host chromosome, integrase has been considered as an
attractive therapeutic target. Numerous compounds have
been described as inhibitors of HIV-1 integrase (for a
recent review, see Ref. [105]): for example, polyamides,
bisdistamycins and lexitropsins [106], polyhydroxylated
aromatic type of compounds, including ellagic acid, pur-
purogallin, 4,8,12-trioxatricornan and hypericin [107] and
a series of thiazolothiazepine derivatives, preferably pos-
sessing the pentatomic moiety SC(O)CNC(O) with two
carbonyl groups [108]. The problem with integrase inhib-
itors is that while they might be effective in an enzyme-
based assay, their anti-HIV activity in cell culture may be
masked by cytotoxicity, and if they do exhibit anti-HIV
activity, this could, at least in some cases, be attributed to
antiviral actions targeted at other steps in the HIV repli-
cative cycle.
L-chicoric acid [109–111] is such a case. L-chicoric acid
is structurally reminiscent of curcumin [112], 3,5-dicaf-
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feoylquinic acid [113], rosmarinic acid [114] and dicaf-
feoyltartaric acids (DCTAs) [115], and all these compounds
have been reported to inhibit HIV-1 integrase. Integrase was
identified as the molecular target for the action of L-chicoric
acid (23) since a single amino acid substitution (G140S) in
the integrase rendered the corresponding HIV-1 mutant
resistant to L-chicoric acid [111]. We have recently demon-
strated [116], however, that L-chicoric acid owes its anti-
HIV activity in cell-culture to an interaction with the viral
envelope gp120. Upon repeated passages of the virus in the
presence of the compound, mutations were found in the V2,
V3 and V4 loop of gp120, while no mutations were seen in
the integrase. We did confirm that in an enzymatic assay L-
chicoric acid inhibited HIV integrase activity, but integrase
carrying the G140S mutation appeared to be as sensitive to
the inhibitory effect of L-chicoric acid as the wild-type
integrase. Furthermore, L-chicoric acid proved inactive
against HIV strains that were resistant to polyanionic
compounds known to interact at the virus adsorption level,
and time-of-addition experiments further corroborated an
interaction of L-chicoric acid at the virus adsorption stage
[116].
Recently, the structure of the HIV-1 integrase core
domain complexed with an inhibitor [1-(5-chloroindol-3-
yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone] has been
described as a platform for structure-based design of novel
HIV-1 integrase inhibitors [117]. This was followed by the
description of a number of diketo acids (such as L-731,988
and L-708,906) as inhibitors of the integrase-mediated
strand transfer reaction that leads to the covalent linkage
of the viral DNA 3Vends to the cellular (target) DNA [107].
These compounds were also found to inhibit HIV-1 repli-
cation in cell culture. Furthermore, mutations in the HIV-1
integrase conferred resistance to the inhibitory effects of
the compounds on both strand transfer and HIV-1 infec-
tivity [118]. Thus, it was surmised that these diketo acids
owe their antiviral activity exclusively to inhibition of one
of the two catalytic functions of integrase, namely strand
transfer [the other catalytic function being endonucleolytic
processing of the (pro)viral DNA to remove the terminal
dinucleotide (GT) from the 3Vend]. Starting from L-731,
988 (24), additional 4-aryl-2,4-dioxobutanoic acid deriva-
tives have been reported as inhibitors of HIV-1 integrase
[119].
9. Transcription (transactivation) inhibitors
At the transcription level, HIV gene expression may be
inhibited by compounds that interact with cellular factors
that bind to the LTR promoter and that are needed for basal
level transcription, such as the NF-nB inhibitors [120].
Greater specificity, however, can be expected from those
compounds that specifically inhibit the transactivation of the
HIV LTR promoter by the viral Tat (trans-activating)
protein [120]. Tat has pleiotropic effects: it not only acti-
vates the transcription of HIV-1 RNA, but also binds to a
number of receptors, i.e. on smooth muscle and skeletal
muscle cells [121]: the basic domain of Tat may be
important, not only for translocation but also for nuclear
localisation and trans-activation, and thus targeting of the
Tat basic domain may provide great scope for therapeutic
intervention in HIV-1 infection [121].
A number of compounds have been reported to inhibit
HIV-1 replication in both acutely and chronically infected
cells through interference with the transcription process: i.e.
fluoroquinoline derivatives [122]. The inhibitory effects of
the fluoroquinolines (K-12) [8-difluoromethoxy-1-ethyl-6-
fluoro-1,4-dihydro-7-[4-(2-methoxyphe-nyl)-1-piperazinyl]-
4-oxoquinoline-3-carboxylic acid] and (K-37) [7-(3,4-dehy-
dro-4-phenyl-1-piperidinyl)-1,4-dihydro-6-fluoro-1-methyl-
8-trifluoromethyl-4-oxoquinoline-3-carboxylic acid] (25) on
the HIV-1 LTR-driven gene expression may at least in part
E. De Clercq / Biochimica et Biophysica Acta 1587 (2002) 258–275268
be attributed to inhibition of Tat [123] or other RNA-
dependent transactivators [124].
The bistriazoloacridone temacrazine [1,4-bis(3-(6-oxo-
6H-v-triazolo[4,5,1]acridin-5-yl-aminopropyl)piperazine]
(26) was found to block HIV-1 RNA transcription from the
HIV proviral DNAwithout interfering with the transcription
of any cellular genes [125]: the compound inhibited HIV-1
replication in both acutely and chronically infected cells.
Resistance was generated upon serial passage of the virus in
the presence of temacrazine and was associated with several
unique nucleotide changes in HIV-1 LTR at positions  1,
 2 and + 111 relative to the start of transcription [126].
Tat peptide analogs, encompassing the Tat core domain
(amino acid residues 36–50) [127], or the basic domain
(amino acids 48–56: RKKRRQRRR) [128] have been
reported to inhibit HIV-1 replication, and, as expected, these
peptide analogs were able to effectively block the Tat
transactivation process. The 9-mer peptoid CGP64222
(27), which is structurally reminiscent of the amino acid
48–56 sequence RKKRRQRRR of Tat, was also reported,
on the one hand, to block the Tat/TAR interaction, and, on
the other hand, to suppress HIV-1 replication [129]. We
have demonstrated, however, that the peptoid CGP64222
owes its anti-HIV activity in cell culture primarily to an
interaction with CXCR4, the coreceptor for X4 HIV strains
[130], which is, perhaps, not surprising given the structural
similarity of CGP64222 to the other, polypeptidic, CXCR4
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antagonists such as T22 [23] and nona-arginine (ALX40-
4C) [24]. In fact, Tat itself (following its extracellular
release) has recently been shown to block CXCR4-depend-
ent HIV-1 infection [131], presumably through blockade of
CXCR4 by the above-mentioned 48–56 amino acid portion
(RKKRRQRRR) of the molecule.
Flavopiridol (L86-8275, HMR1275) is a cyclin-depend-
ent kinase (Cdk) and P-TEFb inhibitor, which is in clinical
trials for the treatment of cancer because of its antiprolifer-
ative properties. P-TEFb is a protein kinase composed of
Cdk9 and cyclin T1 and secures the elongation phase of
transcription by RNA polymerase II (through phosphoryla-
tion of the carboxyl-terminal domain). Tat forms a triple
complex with P-TEFb (composed of Cdk9 and cyclin T1)
and the nascent transcript from the HIV-1 LTR promoter.
Consistent with its ability to block P-TEFb, flavopiridol (28)
was found to block Tat transactivation, and, concomitantly,
also inhibited HIV replication [132].
10. HIV PIs
HIV PIs prevent the cleavage of the gag and gag-pol
precursor polyproteins to the structural proteins (p17, p24,
p7, p6, p2, p1) and functional proteins (protease, RT/RNase
H, integrase), thus arresting maturation and thereby block-
ing infectivity of the nascent virions [133]. The HIV PIs
have been tailored after the target peptidic linkage in the gag
and gag-pol polyproteins that are cleaved by the protease,
viz. the phenylalanine–proline sequence at positions 167
and 168 of the gag-pol polyprotein. All PIs that are currently
licensed for the treatment of HIV infection, namely saqui-
navir, ritonavir, indinavir, nelfinavir, amprenavir and lopi-
navir, share the same structural determinant, i.e. an
hydroxyethylene (instead of the normal peptidic) bond,
which makes them nonscissile substrate analogues for the
HIV protease. All six licensed PIs follow the same principle;
that is, they act as peptidomimetic inhibitors of HIV
protease [134]. Lopinavir is co-dosed with ritonavir at
400/100 mg twice daily. The reason for this combination
is that ritonavir strongly inhibits the metabolism of lopinavir
and allows lopinavir to reach much higher plasma drug
levels upon oral administration [135]. In phase III clinical
trials is atazanavir (BMS-232632) (29), which has been
accredited with a favorable resistance profile that does not
parallel any of the other PIs currently in clinical use, as well
as a favorable pharmacokinetic profile that would allow
once-daily dosing [136].
Resistance mutations have been reported for most, if not
all, peptidomimetric inhibitors of HIV protease. This has
prompted the search for new, nonpeptidic inhibitors of HIV
protease, which, in addition to a broader anti-HIV activity
spectrum, might also offer increased oral bioavailability
and/or pharmacokinetic properties. Examples of nonpeptidic
PIs of HIV protease include 4-hydroxycoumarins and 4-
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hydroxy-2-pyrones [137], sulfonamide-substituted deriva-
tives [138], cyclic ureas (i.e. DMP-323 and DMP-450)
[139,140], cyclic cyanoguanidines [141], aza-dipeptide ana-
logues [142], and tipranavir (PNU-140690), a sulfonamide-
containing 5,6-dihydro-4-hydroxy-2-pyrone [143–145].
The major advantage of the cyclic urea mozenavir (DMP-
450) (30) is its substantial oral bioavailability observed in all
species examined, including man [140]. DMP-450 has been
the subject of phase I/II dose-escalating clinical studies and
appears to have good antiviral activity and tolerability at all
doses tested [146]. The new aza-dipeptide analogues com-
bine excellent anti-HIV potency with high blood drug levels
after oral administration, and, furthermore, they show no
cross-resistance with saquinavir-resistant HIV strains [142].
Tipranavir (31) showed low cross-resistance to HIV strains
that were resistant to the established (peptidomimetic)
inhibitors of HIV protease [145]. Also, tipranavir retained
marked activity against HIV-1 isolates derived from patients
with multidrug resistance to other PIs [147].
Independently of the HIV protease itself, proteasomes
play a role in the processing of the gag polyprotein, and
proteasome inhibitors, such as epoxomicin, have been
shown to inhibit gag polyprotein processing as well as
HIV maturation and release [148]. While a potentially
interesting approach, it remains to be seen whether inhib-
itors of the proteasome/ubiquitin system display sufficient
specificity in their anti-HIV action so as to suppress virus
replication without (overt) cytotoxicity.
11. Conclusions
In recent years, an ever increasing number of compounds
have been uncovered as anti-HIV agents targeted at virtually
any step of the virus replicative cycle: adsorption, entry,
fusion, uncoating, reverse transcription, integration, tran-
scription (transactivation) and maturation. In addition to the
‘‘newer’’ NRTIs, NNRTIs and PIs, various other com-
pounds, i.e. those that are targeted at viral entry (i.e. CXCR4
and CCR5 antagonists) and virus-cell adsorption/fusion (i.e.
compounds interacting with either gp120 or gp41), offer
great potential for the treatment of HIV infections. Quite a
number of compounds are capable of interacting with more
than one target. Two examples in point are the DCTA L-
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chicoric acid, and the nonapeptoid CGP 64222. L-chicoric
acid was originally identified as an integrase inhibitor, and
the nonapeptoid as a transactivation (Tat) antagonist, and
their anti-HIV activity in acutely infected cells was ascribed
to interference with the integration and transactivation proc-
ess, respectively. As it now appears, L-chicoric acid primarily
interacts as a virus adsorption inhibitor, and the nonapeptoid
as a CXCR4 antagonist, and thus these compounds owe their
anti-HIV activity mainly to interference with an early event
(adsorption, entry) of the HIV replicative cycle.
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